IndustryCompany release

NeOnc reports narrower Q3 loss, citing positive Phase 2a NEO100 glioma data

🇺🇸 Neonc Technologies Holdings, Inc. (NTHI) · Thu 05 Nov 2026

NeOnc Technologies posted a Q3 2026 net loss of $4.4M and flagged Phase 2a NEO100 results, FDA feedback on NEO212 and a $15M registered direct offering.

NeOnc Technologies Holdings reported results for the quarter ended 30 September 2026 on 5 November, showing a net loss of $4.4M. That compares with a loss of $8.6M in the same quarter a year earlier.

On the clinical side, the company highlighted positive topline data from a Phase 2a study of intranasal NEO100 in recurrent IDH1-mutant high-grade glioma. The summary available does not give the efficacy figures, so the size of the effect cannot be assessed here.

NeOnc also said it received written feedback from the US Food and Drug Administration on chemistry, manufacturing and controls (CMC) for NEO212, including the planned transition to a tablet formulation. The details of the agency's comments were not provided.

On the corporate side, the company announced a memorandum of understanding with the Abu Dhabi Department of Health in October. It closed a $15M registered direct offering and redeemed its Series A preferred stock. NeOnc plans to present NEO100 and NEO212 data at the Society for Neuro-Oncology (SNO) meeting on 13 November.

What it means for your team

  • The Phase 2a NEO100 readout is topline only; regulatory teams should wait for the full dataset at SNO or in later disclosures before drawing conclusions.
  • FDA written feedback on NEO212 CMC and the tablet transition signals active dialogue on manufacturing and formulation change, a key area for quality and CMC teams.
  • The Abu Dhabi MoU points to potential Middle East engagement, though no commercial or regulatory terms were disclosed.
  • The $15M raise and preferred-stock redemption bear on the company's funding position as it advances both programmes.

Company's press release (SEC filing): Neonc Technologies Holdings, Inc. ↗

Article written by VigiEye from the official source (Neonc Technologies Holdings, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →